APDA News Page 9

APDA-funded Brigham and Women’s Hospital explores the genetic variants associated with Parkinson’s disease and other conditions

Posted on by APDA

APDA-funded Brigham and Women’s Hospital explores the genetic variants associated with Parkinson’s disease and other neuropsychiatric conditions In classic biochemistry,...see more ribonucleic acid (RNA) was thought to be a simple middle man between our genome and our proteins. Recently, however, it has become clear that RNA exists in multiple forms and plays a myriad of roles, including regulating protein production, regulating genome activity, and sensing environment. In fact, only a very small portion of DNA gets transcribed into RNA that creates protein. A much large portion gets transcribed into RNA that has various other functions.

Read More

FDA New Analysis on PD Psychosis Treatment

Posted on by APDA

On September 20, 2018, the FDA recently released results of a new analysis...see more finding no new or unexpected safety risks associated with Nuplazid. The new analysis was initiated because of concerns raised in the media last spring, and reassures patients that they should continue to take Nuplazid as prescribed by their physician. The FDA report highlights a number of important concepts

Read More

Promising results from APDA-funded LRRK2 research

Posted on by APDA

On July 25, 2018, the APDA Center for Advanced Research at the University of...see more Pittsburgh, led by the Center’s Director (and APDA Scientific Advisory Board member), Dr. J. Timothy Greenamyre, published results of a study highlighting the role of Leucine-rich Repeat Kinase (LRRK2) in the development of Parkinson’s disease.

Read More